<p>Breast cancer is type of cancer arises from breast tissues results with lumps and tumor development and has many types out of which one is more aggressive type named, triple-negative breast cancer .researcher from University of Michigan Health System identified one of most promising compound named UM-164 may play an important role in better treatment of triple-negative breast cancer.</p><p>The compound UM-164 mainly blocks protein named kinase c-Src and inhibits another pathway, p38, involved in this subtype. On another way researcher also identified compound had few side effects over results in mice.</p><p>&amp;quot;Triple-negative breast cancer is in dire need of new drugs. The treatments that have dramatically improved breast cancer outcomes don&#039;t apply to patients with this type of disease,&amp;quot; says senior study author Sofia Merajver, M.D., Ph.D., scientific director of the breast oncology program at the University of Michigan Comprehensive Cancer Center.<br /><br /><img src="http://www.microbiozindia.com/images/ASX.png" alt="" /></p><p>Triple negative breats cancer is more aggressive than others and patients could see the results and spread of cancer and the name triple is because this shows negative for two hormone receptors and the HER2 protein.</p><p>&amp;quot;We are gaining a better understanding of the biology of triple-negative breast cancer, which is essential to developing targeted therapies,&amp;quot; says study first author Rabia A. Gilani, Ph.D., a post-doctoral research fellow at U-M.</p><p><strong>Story source: </strong>University of Michigan Health System</p><p>Journal References:</p><p>R. Gilani, S. Phadke, L. W. Bao, E. Lachacz, M. Dziubinski, K. Brandvold, M. Steffey, F. Kwarcinski, C. R. Graveel, K. M. Kidwell, S. D. Merajver, M. B. Soellner. UM-164: a potent c-Src/p38 kinase inhibitor with in vivo activity against triple negative breast cancer. Clinical Cancer Research, 2016; DOI: 10.1158/1078-0432.CCR-15-2158</p>